-
公开(公告)号:US11643458B2
公开(公告)日:2023-05-09
申请号:US17059886
申请日:2019-05-30
申请人: SHIONOGI & CO., LTD.
发明人: Tatsuya Takahashi , Mai Yoshikawa , Sosuke Yoneda , Junji Onoda , Etsuo Nakamura , Tsuguo Miyauchi , Toshiyuki Asaki , Erika Kasai
IPC分类号: A61K39/395 , C07K16/00 , C07K16/46 , C07H21/04 , C12N5/02 , C12N1/20 , C12N15/00 , C07K16/18 , A61P29/00 , A61K39/00
CPC分类号: C07K16/18 , A61P29/00 , A61K2039/505 , C07K2317/565 , C07K2317/64
摘要: Objective of the present invention is to provide a novel monoclonal antibody against Nav1.7. The present invention discloses a monoclonal antibody against Nav1.7 or its antibody fragment, having specific six CDRs (CDR1 to CDR3 of a heavy chain and CDR1 to CDR3 of a light chain) or specific heavy/light chain variable regions. The monoclonal antibody and the like can be used for treating or preventing pain, pruritus and so on.
-
公开(公告)号:US20220064312A1
公开(公告)日:2022-03-03
申请号:US17418417
申请日:2019-12-27
发明人: Mai Yoshikawa , Tatsuya Takahashi , Junji Onoda , Sunao Imai , Etsuo Nakamura , Kentaro Furukawa , Tsuguo Miyauchi , Tetsuya Yoshida , Morio Nagira , Naganari Ohkura , Atsushi Tanaka , Shimon Sakaguchi , Hisashi Wada , Atsunari Kawashima
摘要: Disclosed is a novel anti-CCR8 antibody. The antibody can be used for treating or preventing cancers or the like.
-
公开(公告)号:US20240190975A1
公开(公告)日:2024-06-13
申请号:US18285304
申请日:2022-03-31
发明人: Tetsuya Yoshida , Mai Yoshikawa , Miya Haruna , Morio Nagira , Koji Takahashi , Marina Hayashida , Hiroto Miwa , Yudai Sonoda , Naganari Ohkura , Shimon Sakaguchi , Hisashi Wada
IPC分类号: C07K16/28 , A61K38/00 , A61K39/00 , C07K14/705 , C07K14/725
CPC分类号: C07K16/2866 , A61K39/4611 , A61K39/4612 , A61K39/4613 , A61K39/4631 , C07K14/70503 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , A61K38/00 , A61K2239/13 , A61K2239/17 , A61K2239/21 , A61K2239/22 , C07K2317/24 , C07K2317/622 , C07K2319/02 , C07K2319/03
摘要: The chimeric antigen receptor that recognizes CCR8 as an antigen of the present invention has cytotoxic activity against CCR8-expressing cells by being expressed in effector cells.
-
-